Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H20ClNO2 |
Molecular Weight | 317.81 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC2=C(C=C(O)C(O)=C2Cl)[C@H](C1)C3=CC(C)=CC=C3
InChI
InChIKey=JXMYTVOBSFOHAF-OAHLLOKOSA-N
InChI=1S/C18H20ClNO2/c1-11-4-3-5-12(8-11)15-10-20(2)7-6-13-14(15)9-16(21)18(22)17(13)19/h3-5,8-9,15,21-22H,6-7,10H2,1-2H3/t15-/m1/s1
Molecular Formula | C18H20ClNO2 |
Molecular Weight | 317.81 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12921854Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17207791
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12921854
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17207791
(R)-SKF-83959 (MCL 202) is enantiomer of D1 receptor agonist SKF-83959. (R)-SKF-83959 is reported to be a functionally selective dopamine D1 and D5 receptors ligand with much lower affinity to dopamine D2 and D3 receptors. (R)-SKF-83959 like SKF-83959, produced dose related effects on overt behavior (eye blinking) and schedule-controlled performance in squirrel monkeys. (R)-SKF-83959 increases in eye blinking and decreases in rates of fixed-ratio responding. In contrast to the effects of its S-(-) enantiomer, was relatively devoid of behavioral activity up to doses that were approximately 10-fold greater than (R)-SKF-83959. Pretreatment with the selective D1- like receptor antagonist SCH 39166 dose-dependently antagonized increases in eye blinking produced by (R)-SKF-83959, confirming the involvement of D1 mechanisms in its effects.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2056 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12921854 |
0.49 nM [Ki] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12921854 |
515.0 nM [Ki] | ||
Target ID: CHEMBL1850 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12921854 |
1.53 nM [Ki] | ||
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12921854 |
88.6 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17207791
Rats were treated with (R)-SKF-83959 (0.0003–1.0 mg/kg) as single i.m. injection
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12921854
(R)-SKF-83959 was assayed for affinity at dopamine receptors in rat caudate – putamen tissue from adult male Sprague–Dawley rats. Fresh, rapidly dissected brain tissue was hand-homogenized in 50 mM Tris–HCl buffer pH 7.4, dopamine D1 receptor assays, tissue was incubated with (R)-SKF-83959 or [3H]SCH-23390 (0.30 nM) for 30 min at 30C, using excess cis-flupenthixol (10 mkM) as a blank
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:40:57 GMT 2023
by
admin
on
Sat Dec 16 10:40:57 GMT 2023
|
Record UNII |
39YLC3L0ZU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
39YLC3L0ZU
Created by
admin on Sat Dec 16 10:40:57 GMT 2023 , Edited by admin on Sat Dec 16 10:40:57 GMT 2023
|
PRIMARY | |||
|
652994-63-3
Created by
admin on Sat Dec 16 10:40:57 GMT 2023 , Edited by admin on Sat Dec 16 10:40:57 GMT 2023
|
PRIMARY | |||
|
9995976
Created by
admin on Sat Dec 16 10:40:57 GMT 2023 , Edited by admin on Sat Dec 16 10:40:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER |